The cost of Anoro Ellipta can vary significantly based on factors such as insurance coverage, pharmacy, and geographic location. A typical retail price for Anoro Ellipta (umeclidinium/vilanterol) 62.5 mcg-25 mcg inhalation powder, 1 device with 30 doses, can range from approximately $400 to over $600 [1].
How can I get Anoro Ellipta for less?
Patients may be able to reduce the cost of Anoro Ellipta through several avenues. Pharmaceutical manufacturer coupons or patient assistance programs might offer discounts [2]. Additionally, comparing prices at different pharmacies can reveal significant savings [1]. Some insurance plans may also cover a portion of the cost, or a generic version may become available in the future, potentially lowering expenses [3].
When does Anoro patent expire?
Understanding Anoro's patent expiration is crucial for predicting future cost changes, especially with the potential emergence of generic alternatives. DrugPatentWatch.com tracks patent information for medications like Anoro [4]. While specific patent expiry dates can be complex due to multiple patents and legal challenges, information on these dates can be found through specialized patent databases [4].
How does Anoro Ellipta work?
Anoro Ellipta is a combination inhaler that contains two bronchodilators: umeclidinium and vilanterol. Umeclidinium is a long-acting muscarinic antagonist (LAMA), and vilanterol is a long-acting beta2-adrenergic agonist (LABA) [5]. Together, these ingredients work to relax and open the airways, making breathing easier for individuals with chronic obstructive pulmonary disease (COPD) [5].
What is Anoro Ellipta used for?
Anoro Ellipta is prescribed for the long-term maintenance treatment of airflow obstruction in patients with COPD [5]. This includes chronic bronchitis and emphysema. It is not intended for immediate relief of bronchospasm or as a rescue inhaler for asthma [5].
What are the common side effects of Anoro Ellipta?
Common side effects associated with Anoro Ellipta may include nasopharyngitis (common cold symptoms), upper respiratory tract infection, bronchitis, and chest pain [5]. Other reported side effects can involve headache, joint pain, increased blood pressure, and irregular heart rhythms [5]. It is important for patients to discuss any experienced side effects with their healthcare provider.
How does Anoro compare to other COPD inhalers?
Anoro Ellipta belongs to a class of medications known as long-acting bronchodilators, which also includes other LAMAs, LABAs, and dual bronchodilators (LAMA/LABA combinations) [6]. Its effectiveness and side effect profile are compared against other single-agent bronchodilators and other combination therapies in clinical trials and real-world studies [6]. The choice of inhaler often depends on individual patient needs, symptom severity, and response to treatment [6].
What clinical trials have been done for Anoro?
Extensive clinical trials have been conducted to evaluate the efficacy and safety of Anoro Ellipta. These studies have generally compared Anoro to placebo or other active treatments in patients with moderate to very severe COPD [7]. Key trial outcomes often focus on improvements in lung function, reductions in exacerbations (COPD flare-ups), and patient-reported symptoms [7].
What is the difference between Anoro and Trelegy?
Both Anoro Ellipta and Trelegy Ellipta are once-daily inhaled medications for COPD, but they contain different combinations of active ingredients [8]. Anoro Ellipta is a dual bronchodilator containing a LAMA and a LABA (umeclidinium/vilanterol) [5]. Trelegy Ellipta, on the other hand, is a triple therapy that includes a LAMA, a LABA, and an inhaled corticosteroid (ICS) (fluticasone furoate/umeclidinium/vilanterol) [8]. Trelegy is typically prescribed for patients whose COPD is not adequately controlled with a LAMA/LABA combination therapy [8].
Can a generic version of Anoro Ellipta be made?
The development of generic versions of Anoro Ellipta depends on patent expiration and regulatory approval processes [3][4]. Once relevant patents expire and a generic manufacturer demonstrates bioequivalence, a generic version could become available, potentially leading to lower costs [3].
---
Sources:
[1] https://www.goodrx.com/anoro-ellipta
[2] https://www.anoro.com/savings-and-support
[3] https://www.drugpatentwatch.com/
[4] https://www.drugpatentwatch.com/drugs/anoro-ellipta
[5] https://www.anoro.com/
[6] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3957060/
[7] https://clinicaltrials.gov/ct2/show/NCT01585212
[8] https://www.trelegy.com/